1stOncology™: Cancer Intelligence Service – Page 8993 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

X‑Chem Acquires ComInnex

On October 25, 2021 X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, reported the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market.

"As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide," noted Matt Clark, Ph.D., CEO of X-Chem. "The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help biopharma clients of any size efficiently unlock exponential possibilities in small molecule drug discovery."

"Combining X-Chem, the world leader and pioneer of high-quality DEL technology, and ComInnex, a leader in the most important trends and novel approaches in early-stage drug discovery chemistry, will yield a powerhouse partner for innovative drug discovery solutions," commented Alex Drijver, CEO of ComInnex.

ComInnex’s technology expertise in flow chemistry, photochemistry and software development will expand X-Chem’s capabilities supporting the creation and delivery of innovative services for drug developers on a global scale.

(Press release, X-Chem, OCT 25, 2021, View Source [SID1234664774])

Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results

On October 25, 2021 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, reported it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021 (Press release, Delcath Systems, OCT 25, 2021, View Source [SID1234595188]).

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

The call will also be available over the Internet and accessible at:

View Source

Israel’s Silenseed Raises $7.8 Million for China RNAi Joint Venture

On October 25, 2021 Silenseed, a Tel Aviv RNAi company, reported that it raised $7.8 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to start a China JV (Press release, Silenseed, OCT 25, 2021, View Source [SID1234593957]). Silenseed-China will own the rights to develop, market and sell Silenseed’s RNAi products in China. The Israeli company will use the capital to conduct a Phase III trial of its lead candidate, which targets the KRAS oncogene to treat pancreatic cancer. Silenseed’s novel drug delivery platform enables the insertion of RNAi therapeutics directly into solid tumors. GIBF will own a 49% stake in the Silenseed Chinese subsidiary.

Entry into a Material Definitive Agreement

On October 25, 2021, Oncotelic Therapeutics, Inc. (the "Company") reported that it entered into an Unsecured Convertible Note Purchase Agreement (the "Purchase Agreement") with Golden Mountain Partners, LLC (the ("Holder"), pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million (the "Note"), which Note is convertible into shares of the Company’s common stock, par value $0.01 per share ("Common Stock") (Filing, 8-K, Mateon Therapeutics, OCT 25, 2021, View Source [SID1234592110]).

The Note carries an interest rate of 2% per annum and matures on the earlier of (a) the one-year anniversary of the date of the Agreement, or (b) the acceleration of the maturity of the Note by Holder upon occurrence of an Event of Default (as defined below). The Note contains a voluntary conversion mechanism whereby the Holder may convert the outstanding principal and accrued interest under the terms of the Note into shares of Common Stock (the "Conversion Shares"), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion (as defined in the Note) from Holder. Prepayment of the Note may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The Note contains customary events of default (each an "Event of Default"). If an Event of Default occurs, at the Holder’s election, the outstanding principal amount of the Note, plus accrued but unpaid interest, will become immediately due and payable in cash. The Purchase Agreement requires the Company to use of the proceeds received under the Note to support the clinical development of OT-101, including payroll and has been made in continuation of the relationship between the Company and the Holder.

The issuance of the Note is exempt from the registration requirements of the Securities Act of 1933, as amended ("Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of Common Stock issuable upon conversion of the Note have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

The foregoing descriptions of the Purchase Agreement and the Note are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibit 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.

Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events

On October 25, 2021 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported that Gritstone management will participate in five upcoming investor conferences in October, November and December (Press release, Gritstone Oncology, OCT 25, 2021, View Source [SID1234592018]).

Conference: B. Riley Fall Best Ideas in Oncology Panel Series – Overcoming Checkpoint Resistance in Solid Tumors
Date and Time: Thursday, October 28, 2021 at 11:00 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer

Conference: Stifel 2021 Virtual Healthcare Conference
Date and Time: Monday, November 15, 2021 at 1:20 p.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer

Conference: Cowen’s 5th Annual IO Next Virtual Summit
Date and Time: Monday, November 15, 2021 at 4:15 p.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer

Conference: Evercore ISI 4th Annual Health CONx Virtual Conference
Date and Time: Wednesday, December 1, 2021 at 10:05 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer

Conference: Piper Sandler 33rd Annual Healthcare Conference
Date and Time: November 30-December 2, 2021
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer

A live webcast of the presentations will be accessible via the Investors & Media section of the company’s website at View Source An archived replay will be accessible for 30 days following each event.